Atlas Trials

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients

Clinical trial NCT06421831 · RECRUITING

Trial details

NCT number
NCT06421831
Sponsor
GeneCradle Inc
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Spinal Muscular Atrophy Type 3
Start date
2024-05-10
Primary completion
2026-12-01
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.